重磅!百亿美元豪赌!吉利德想靠CAR-T再赢一次!

谈思生物
18 Dec 2024

82024.12.18本文字数:3135,阅读时长大约2分钟导读:吉利德在抗肿瘤领域的最新动态成为焦点,尤其是在BCMA CAR-T疗法“anito-cel”的临床数据公布后,市场对其能否超越竞争对手“Carvykti”充满期待。近两年,吉利德似乎一直处在水逆之中。除了长效HIV疗法,几乎没有什么好消息,尤其是在吉利德持续加大投入的抗肿瘤领域,甚至可以说是越努力越感到失望。不仅在TIGIT等布局上...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10